Ziopharm Chief Medical Officer Francois Lebel to Step Down

Francois Lebel, chief medical officer of Ziopharm Oncology (NASDAQ: [[ticker:ZIOP]]), plans to step down from his position effective Oct. 26. The Boston cancer drug developer gave no reason for Lebel’s decision to leave the company. In a securities filing, Ziopharm said Lebel gave his notice on Oct. 10. Lebel has been Ziopharm’s chief medical officer since 2015, according to Bloomberg executive profile. In other moves, Ziopharm appointed CEO Laurence Cooper to its board of directors. Ziopharm develops cell and gene therapies to treat cancer.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan